Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
- Citation:
- Angiogenesis vol 25 (1) 47-55
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 11
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Abraxis BioScience, Bristol Meyers Squibb, Celgene, Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233327, UG1CA233337, UG1CA233373
- Corr. Author:
- Authors:
- Julia C. F. Quintanilha Yingmiao Liu Amy S. Etheridge Akram Yazdani Hedy L. Kindler William Kevin Kelly Andrew B. Nixon Federico Innocenti
- Networks:
- LAPS-IL057, LAPS-NC007, LAPS-NC010
- Study
- Alliance-A152114
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-80303, CALGB-90401
- Phases:
- N/A, 3
- Keywords:
- Bevacizumab, hypertension, angiopoietin-2, VEGF-A, VCAM-1